Treatment of Inflammatory Bowel Disease with Azathioprine: How to Use It in 1999

[en] Azathioprine and 6-mercaptopurine are effective drugs in the management of steroid dependent and chronic active inflammatory bowel diseases. They are also well tolerated on the long term. However, their use is still hampered by some drawbacks including delay before efficacy, 20-35% of non responders, relapse at withdrawal of the drugs, possible bone marrow toxicity and other side effects. During the last few years, these drawbacks have been challenged by important studies showing that a better knowledge of the metabolism of these drugs may help to improve their use.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

English

Title :

Treatment of Inflammatory Bowel Disease with Azathioprine: How to Use It in 1999

Publication date :

1999

Journal title :

Acta Gastro-Enterologica Belgica

ISSN :

0001-5644

eISSN :

1784-3227

Publisher :

Acta Medica Belgica, Bruxelles, Belgium

Volume :

Issue :

4, Oct-Dec

Pages :

437-9

Available on ORBi :

since 26 November 2009

Statistics

Number of views

21 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Summers, R.W., Switz, D.M., Sessions, J.T., Becktel, J.M., Best, W.R., Kern F., Jr., National cooperative Crohn's disease study : Results of drug treatment (1979) Gastroenterology, 77, pp. 847-869
Pearson, D.C., May, G.R., Fick, G.H., Sutherland, L.R., Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis (1995) Ann. Intern. Med., 123, pp. 132-142
Present, D.H., Korelitz, B.I., Wisch, N., Glass, J.L., Sachar, D.B., Pasternack, B.S., Treatment of Crohn's disease with 6-mercaptopurine : A long-term, randomized, double-blind study (1980) N. Engl. J. Med., 302, pp. 981-987
Connell, W.R., Kamm, M.A., Dickson, M., Balkwill, A.M., Ritchie, J.K., Lennard-Jones, J.E., Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease (1994) Lancet, 343, pp. 1249-1252
Blondel-Kucharski, F., Chircop, C., Marquis, P., Colombel, J.F., Gendre, J.P., Qualité de vie au cours de la maladie de Crohn. Etude prospective longitudinale de 231 patients (1999) Gastroenterol. Clin. Biol., 23, pp. A85
Sandborn, W.J., Van Os, E., Zins, B.J., Tremaine, W.J., Mays, D.C., Lipsky, J.J., An Intravenous Loading Dose of Azathioprine Decreases the Time to Response in Patients with Crohn's Disease
Sandborn, W.J., Tremaine, W.J., Wolf, D.C., Targan, S.R., Sninsky, C.A., Sutherland, L.R., Hanauer, S.B., Murdock, R.H., A randomized, double-blind, placebo-controlled, multicenter trial of intravenous azathioprine loading to decrease the time to response in steroid-refractory Crohn's disease (1998) Digestion, 59, pp. GaPP0045
Louis, E., Dupont, P., Depauw, A., Croes, F., Demolln, G., Belaiche, J., Rapide anti-inflammatory effect of high dose azathioprine in inflammatory bowel disease : An in vitro study (1998) Gastroenterology, 114, pp. G4206
Barbe, L., Marteau, P., Lémann, M., Bouhnik, Y., Allez, M., Coffin, B., Bonnett, J., Modigliani, R., Dose raising of azathioprine beyond 2.5 mg/Kg/day in Crohn's disease patients who fail to improve with a standard dose (1998) Gastroenterology, 114, pp. G3794
Colonna, T., Korelitz, B.I., The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease (1994) Am. J. Gastroenterol., 89, pp. 362-366
Cuffari, C., Théorêt, Y., Latour, S., Seidman, G., 6-mercaptopurine metabolism in Crohn's disease : Correlation with efficacy and toxicity (1996) Gut, 39, pp. 401-406
Bergan, S., Rugstad, H.E., Bentdal, O., Sodal, G., Hartmann, A., Leivestad, T., Stokke, O., Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation (1998) Transplantation, 66, pp. 334-339
Lennard, L., Lilleyman, J.S., Van Loon, J., Weinshilboum, R.M., Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia (1990) Lancet, 336, pp. 225-229
Lennard, L., Rees, L.A., Lilleyman, J.S., Maddocks, J.L., Childhood leukaemia : A relationship between intracellular 6-mercaptopurine metabolises and neutropenia (1983) Br. J. Clin. Pharmacol., 16, pp. 359-363
O'Donoghue, D.P., Dawson, A.M., Powel-Tuck, K., Bown, R.L., Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease (1978) Lancet, 2, pp. 944-946
Korelitz, B.I., Adler, D.J., Mendelsohn, R.A., Sacknoff, A., Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease (1993) Am. J. Gastroenterol., 88, pp. 1198-1205
Bouhnik, Y., Lémann, M., Mary, J.-Y., Scemama, G., Taï, R., Matuchansky, C., Modigliani, R., Rambaud, J.-C., Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine (1996) Lancet, 347, pp. 215-219
Connell, W.R., Kamm, M.A., Ritchie, J.K., Lennard-Jones, J.E., Bone marrow toxicity caused by azathioprine in inflammatory bowel disease : 27 years of experience (1993) Gut, 34, pp. 1081-1085
Krynetski, E.Y., Tai, H.L., Yates, C.R., Fessing, M.Y., Loennechen, T., Schuetz, J.D., Reeling, M.V., Evans, W.E., Genetic polymorphism of thiopurine S-methyltransferase : Clinical importance and molecular mechanisms (1996) Pharmacogenetics, 6, pp. 279-290
Bergan, S., Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements (1997) BioDrugs, 8, pp. 446-456
Bergan, S., Rugstad, H.E., Klemetsdal, B., Giverhaug, T., Bentdal, O., Sodal, G., Hartmann, A., Stokke, O., Possibilities for therapeutic drug monitoring of azathioprine : 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells (1997) Ther. Drug Monit., 19, pp. 318-326
Szumlanski, C.L., Weinshilboum, R.M., Sulfasalazine inhibition of thiopurine methyltransferase : Possible mechanism for interaction with 6-mercaptopurine and azathioprine (1995) Br. J. Clin. Pharmac., 39, pp. 456-459
Chocair, P.R., Duley, J.A., Simmonds, H.A., The importance of thiopurine methyltransferase activity for the use of azathioprine in kidney transplant recipients (1992) Transplantation, 53, pp. 1051-1056
Evans, W.E., Homer, M., Chu, Y.Q., Kalwinsky, D., Roberts, W.M., Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyl-transferase deficient child with acute lymphocytic leukemia (1991) J. Pediatr., 119, pp. 985-989
Present, D.H., Meltzer, S.J., Krumholtz, M.P., Wolke, A., Korelitz, B.I., 6-mercaptopurine in the managment of inflammatory bowel disease : Short-and long-term toxicity (1989) Ann. Intern. Med., 111, pp. 641-649
Léman, M., Bouhnik, Y., Kmieciak-Le Corguille, M., Bonnet, J., Coffin, B., Marteau, P., Bitoun, P., Rambaud, J.C., Treatment of Crohn's disease (CD) with 6-mercaptopurine (6-MP) in patients intolerant to azathioprine (AZA) (1997) Gastroenterology, 112, pp. A1025